Hemorrhagic cystitis is a diffuse inflammation of the mucosa of the bladder, characterized by hematuria and burning upon urination. This might be caused by a variety of reasons, including undergoing chemotherapy (such as cyclophosphamide), radiation therapy, bladder cancer, certain viruses, urinary infections, and thrombocytopenia. There are no previous reports of hemorrhagic cystitis associated with the use of tacrolimus. This is the first case of hemorrhagic cystitis due to tacrolimus for the treatment of rheumatoid arthritis. We describe a case of hemorrhagic cystitis with giant cells in a patient with rheumatoid arthritis treating with tacrolimus. Hematuria resolved spontaneously with discontinuation of the drug.
Introduction
Hemorrhagic cystitis (HC) is a diffuse inflammation of the mucosa of the bladder. It is characterized by gross hematuria and irritating voiding symptoms such as dysuria, with frequency and urgency (1) . The reasons behind this may include undergoing chemotherapy (such as cyclophosphamide), using drugs (such as atrovastatin, penicillin G), radiation therapy, bladder cancer, certain viruses, urinary infections, and thrombocytopenia (1, 2) . In particular, chemotherapy and radiation therapy are the cancer treatment modalities that account for the majority of the causes of this urologic emergency.
Tacrolimus is useful for the treatment of rheumatoid arthritis (RA), but has several side effects. We describe the first case of HC, with giant cells, in a 73-year-old female patient with RA, who is being treated with Tacrolimus.
Case Report
A 73-year-old woman was suffering from urinary frequency and gross hematuria for three days. The urine was pink-tinged with an occasional small clot. She was initially treated, empirically, with sulfamethoxazole/trimethoprim for a presumed urinary tract infection, but showed no change in symptoms.
She was referred for further urologic evaluation. The patient denied any prior urologic history, and did not have a history of smoking. She had been treated for RA and interstitial lung disease (ILD, Figure 1A ) with corticosteroid and methotrexate (MTX, 10 mg/week), hydroxychloroquine (300 mg/day), and sulfasalazine (2.0 g/day) for four years. She had responded inadequately to above anti-rheumatic drugs and had relative contraindication of MTX and leflunomide due to ILD. Thus, she was treated with corticosteroid and Tacrolimus (3 mg/day) for one year. There was no change in other anti-rheumatic drugs, also any use of cyclophophamide. Her temperature was 36. 
Discussion
The bladder is vulnerable to the adverse effects of many drugs because of its intimate exposure to toxins and drug metabolites in the urine (3). One of the very rare adverse reactions to several drugs is HC. This results from damage to the bladder transitional epithelium and blood vessels by toxins, drugs, viruses, radiation, or disease (1, 2) . This is a well-described complication of cancer treatment for patients 
Summary
Although there is lack of experimental and epidemiological evidence, it is possible that HC with giant cells can occur in RA during treatment with Tacrolimus. Thus, we propose the recognition of this casual relationship and early diagnosis, and suggest that prompt medical treatment is mandatory to avoid unnecessary investigations and improve the outcome.
